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Abstract
Familial Hypercholesterolemia (FH) is a common cause of premature cardiovascular disease and is often
undiagnosed in young people. Although the disease is diagnosed clinically by high LDL cholesterol levels and
family history, to date there are no single internationally accepted criteria for the diagnosis of FH. Several genes
have been shown to be involved in FH; yet determining the implications of the different mutations on the
phenotype remains a hard task. The polygenetic nature of FH is being enhanced by the discovery of new genes
that serve as modifiers. Nevertheless, the picture is still unclear and many unknown genes contributing to the
phenotype are most likely involved. Because of this evolving polygenetic nature, the diagnosis of FH by genetic
testing is hampered by its cost and effectiveness.
In this review, we reconsider the clinical versus genetic nomenclature of FH in the literature. After we describe
each of the genetic causes of FH, we summarize the known correlation with phenotypic measures so far for each
genetic defect. We then discuss studies from different populations on the genetic and clinical diagnoses of FH to
draw helpful conclusions on cost-effectiveness and suggestions for diagnosis.
Introduction
Familial Hypercholesterolemia (FH) (MIM #143890) is a
genetic disease characterized by elevated LDL-Cholesterol
(LDL-C), which deposits in the tissues causing the external
manifestations of the disease, namely tendinous xantho-
mas, xanthelasmas, and corneal arcus. More importantly,
LDL-C deposits in blood vessels leading to premature car-
diovascular disease [1,2]. The patterns of inheritance of
FH were first described by Khachadurian in Lebanon
before the genes that contribute to the disease were
known [3]. FH was defined as an autosomal dominant dis-
ease, with a clinical distinction based on phenotype sever-
ity of a “heterozygous” and a “homozygous” form, with
serum LDL-C levels that are two times and four times the
normal respectively [3]. The prevalence of the severe phe-
notype has been reported as 1 in a million in the general
population, compared to the much more common mild
form with a prevalence of 1 in 500 [1]. The prevalence has
been reported to be ten times higher in certain popula-
tions with a presumed founder effect, such as the Leba-
nese, the French Canadians, and the South Afrikaners
[1,2]. A less common autosomal recessive pattern of
inheritance was also described in some of the initial Leba-
nese families [3].
In 1986, the LDL receptor (LDLR) was discovered as the
cause of Autosomal Dominant Hypercholesterolemia
(ADH) [4]. It manifests a gene dosage effect such that the
heterozygous and homozygous forms cause mild and
severe phenotypes respectively. For years, ADH was
thought of as a monogenetic disease. However, as more
genotyping of FH patients was carried, patients with the
phenotype but no LDLR mutation were discovered, and
the search for other genes yielded the discovery of the
Apolipoprotein B gene (ApoB) in 1987 [5], and the Pro-
protein Convertase Subtilin/Kexin 9 gene (PCSK9)i n2 0 0 3
[6], as candidate genes in ADH. The Autosomal Recessive
Hypercholesterolemia gene (ARH) was also discovered in
2001 [7]. These discoveries together fostered the idea of a
polygenetic nature of FH.
Clinically, the severe phenotype is rarely missed with
LDL-C levels that are four times higher than the normal
and external manifestations since early childhood [3].
Additionally, family history is often informative of similar
cases. The clinical diagnosis of the mild phenotype is
much more challenging with external manifestations that
might be absent or appear only in adulthood. LDL-C
could also vary between upper normal levels to double
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revealing. Early diagnosis of FH is crucial because the dis-
ease can be treated with lipid lowering therapy and life-
style changes early on to prevent complications [1].
Failure to diagnose and treat FH leads to increased mor-
bidity and mortality from premature cardiovascular dis-
ease [1,8,9].
Currently, FH can be diagnosed either clinically or
genetically. The use of genetic terminologies to describe
phenotypic presentations of the disease creates confusion
in the literature. In this review, we set up a standard ter-
minology for clinical and genetic descriptions of FH. We
then describe the different molecular mechanisms that
lead to FH and the known genotype-phenotype correla-
tions. We finish by discussing the clinical versus genetic
diagnosis of FH and by looking into worldwide models of
genetic diagnosis and their mutation detection rates.
Terminology Used to Describe Familial
Hypercholesterolemia
Clinicians still use the terms “homozygous” and “hetero-
zygous” to describe a phenotypic presentation of FH. In
Lebanon, severely affected patients are labeled as ‘homo-
zygous” based on clinical assessment and are referred
for LDL apheresis therapy. Screening this population
recently, we have shown that less than half of them are
true homozygous for an LDLR mutation. The rest were
either combined heterozygous for two different muta-
tions, were heterozygous for one mutation, or had no
detectable mutation [10]. Only few countries currently
have national genetic screening programs for FH. Cho-
lesterol levels together with other clinical indicators
remain the most used method to diagnose familial
hypercholesterolemia. In table 1, we suggest a distinc-
tion in the clinical versus genetic nomenclature of FH
based on whether the phenotype or the genotype is
being used for diagnosis.
For familial clustering of cases of elevated cholesterol
levels, a clinical or a genetic assessment is done. A clini-
cal assessment of the phenotype is difficult to categorize.
It is inaccurate for the most of the cases since lipid
levels represent a spectrum and since many non-genetic
factors can affect lipid levels and disease manifestations.
To simplify, we classify the clinical nomenclature into
severe, mild, and paradoxical (Table 1). While mild and
severe represent two clear ends of the spectrum, para-
doxical cases are those that have a more confusing pre-
sentation. A genetic nomenclature on the other hand
should be used only when genotyping of the four candi-
date genes has been made. Heterozygous, homozygous,
or combined heterozygous mutations can thus be identi-
fied (Table 1). When no mutation is detected in a mild
or severe clinically diagnosed FH case, the genetic cause
is unknown. When no mutation is identified in a para-
doxical case, non-familial hypercholesterolemia should
be considered.
Molecular Pathways of Familial Hypercholesterolemia
The Molecular Pathway for the Uptake and Degradation of
LDL-C by the Cell
The pathway was first described by Brown and Gold-
stein in 1986 [4]. LDL in the blood has Apolipoprotein
B-100 (ApoB-100) on its surface. The LDL receptor
(LDLR) is a glycoprotein found on the surface of hepa-
tocytes and binds ApoB-100 of the LDL-C. A clathrin-
coated pit is formed and both receptor and LDL-C
ligand are taken into an endosome with other proteins
via interactions involving the LDLR adaptor protein 1
(LDLRAP1). After dissociation of the ligand-receptor
complex, LDLR is recycled to the cell membrane, while
free cholesterol is used inside the cell. PCSK9 serves as
a post-transcriptional LDLR inhibitor. It is secreted out-
side the cell and inhibits LDLR through cell surface
interactions. Evidence also suggests an intracellular
Table 1 Distinction in the Clinical Versus Genetic Nomenclature of Familial Hypercholesterolemia
Genetically (Genotype)
Homozygous Homozygous for a mutation in one of the candidate genes
a known to cause FH
Combined Heterozygous Heterozygous for two different mutations in the same or different candidate genes known to cause FH
Heterozygous Heterozygous for a mutation in one of the candidate genes known to cause FH
Unknown No causative mutation could be detected after screening all candidate genes known to cause FH
Clinically (Phenotype)
Severe LDL-C levels that are three to four times the normal and external
b or cardiovascular
c manifestations of FH
Mild Elevated LDL-C levels that do not exceed three times the normal
Pardoxical LDL-C levels that are three to four times the normal and with no external or cardiovascular manifestations of FH
OR
Normal to slightly elevated LDL-C levels with external or cardiovascular manifestations of FH
a Candidate genes include LDLR, ApoB, PCSK9,a n dARH/LDLRAP1.
b External manifestations means one or more of tendinous xanthomas, xanthelasmas, or corneal arcus.
c Cardiovascular manifestations means the presence of premature cardiovascular disease as judged clinically.
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the exact mechanism is yet to be elucidated [11].
Nuclear regulation of LDLR production includes two
p a t h w a y s .F i r s t ,t h eb i n d i n g of a Steroid Response Ele-
ment Binding Protein (SREBP) to a Steroid Response
Element (SRE) on the DNA stimulates the transcription
of the LDLR in response to decreased intracellular cho-
lesterol [11]. This pathway is activated during treatment
with HMG-CoA Reductase inhibitors. The second player
in LDLR regulation is another sterol-mediated nuclear
receptor LXR, which was recently shown to induce the
transcription of IDOL (Inducible Degrader of the
LDLR). As its name implies, IDOL triggers ubiquitiniza-
tion of the LDLR targeting it for degradation [12].
(Figure 1) This pathway ensures proper uptake of LDL-
C from the blood. Any defect in this pathway results in
improper uptake and high LDL-C in the blood leading
to the clinical manifestations of FH.
LDLR
Am u t a t i o ni nLDLR (MIM#s 606945, 143890) is by far
the most common cause of ADH. Null alleles produce
no LDL receptors. Other alleles produce defective LDL
receptors. A defective LDLR does not localize to the
nuclear membrane, does not properly bind the LDL-C
particle, or fails to internalize into the cell after binding
[4]. The LDLR gene is located on 19p13 and is 45 kb
long [13]. It is composed of 18 exons that code for an
860 amino acid long peptide. The LDLR protein has
different domains including a signal peptide, a ligand-
binding domain, an epidermal growth factor-precursor
like domain, as well as O-linked sugars, transmembrane,
and cytoplasmic domains [14,15]. Mutations are widely
distributed along all domains of the LDLR protein
and hence can result in different types of dysfunction.
(Table 2) Since the discovery of the LDLR in the mid
1980s, the number of mutations has been continuously
increasing. Currently, the University College of London
database for the LDLR sequence variants lists more than
1700 hits [16,17]. Among them are nonsense substitu-
tions or large deletions that result in absent or truncated
LDLR, missense mutations that result in dysfunctional
receptor, or silent mutations and other polymorphisms
that do not significantly affect the function of the recep-
tor. Many LDLR mutations are population specific, and
many populations have a number of mutations that
leads to the phenotype. In 1987, a nonsense mutation in
exon 14 of the LDLR leading to a truncated receptor
was discovered in Lebanese families and named the
“Lebanese allele” [18]. This allele has always been asso-
ciated with the Christian-Lebanese and people with
Arab ancestry in the West [19,20]. Not until recently
did our team study LDLR mutations in Lebanon and
show that the Lebanese allele accounts to no more than
45% of the clinically homozygous FH patients [10].
A recent study from Tunisia shows that only 5 LDLR
mutations are specific for the population with one of
them accounting to 29.67% of cases [21]. Another exam-
ple comes from Quebec where more than 90% of the
heterozygous FH patients have one of eleven LDLR
mutations [22].
Apo B-100
Apolipoprotein B-100 (ApoB-100) is a protein compo-
nent of the LDL particle. It is found on 2p24-p23. The
gene is made up of 29 exons spanning ~43 Kb and
encoding two main isoforms, ApoB-48 and ApoB-100.
In Familial Defective Apolipoprotein B (MIM #s 107730,
144010), LDL-C fails to bind to its ligand and remains
high in the circulation [5]. There is a limited number of
mutations in ApoB-100 that can cause the FH pheno-
type. The Arg3500Gln variant is the most famous [23].
It is common in Europe accounting to 2-5% of the FH
phenotype [24]. Another variant at the same position
(Arg3500Trp) is common in the Chinese population
[25]. As a cause of ADH, ApoB-100 is relatively uncom-
mon compared to LDLR mutations. (Table 2)
PCSK9
The Proprotein Convertase Subtilin/Kexin Type 9 gene
(PCSK9; MIM# 607786) spanning 3.6 Kb on 1p32
emerged as a third locus involved in ADH, with the dis-
covery in 2003 of two disease-causing mutations in the
French population [6]. The gene spans ~25 Kb, and the
6 9 5a ap r o t e i ni se n c o d e db yt w e l v ee x o n s .PCSK9
binds to the Epidermal Growth Factor-Like Repeat A
(EGF-A) domain of the LDLR inducing its degradation.
Reduced LDLR levels could thus lead to hypercholester-
olemia. Over the past seven years, PCSK9 has been
heavily investigated in many populations with FH, and
the databases currently list 161 sequence variants dis-
tributed along all twelve exons of the gene [14,15].
(Table 2) PCSK9 mutations can affect the phenotype in
different ways. Gain of function mutations are rare and
are associated with decreased LDLR on the surface and
a severe phenotype of FH [6]. Loss of function muta-
tions on the other hand are associated with decreased
cholesterol levels [26]. Moreover, many SNPs exist in
PCSK9 and affect cholesterol regulation differently in
different populations. As a cause of ADH, PCSK9 is
rare compared to LDLR and ApoB-100; however, large
numbers of PCSK9 polymorphisms are associated with
cholesterol levels in population studies [27]. Recent stu-
dies are focusing on the potential of PCSK9-inhibiting
compounds as a therapeutic target for dyslipidemias
[28-30].
ARH
Since the initial observations on the mode of inheritance
of FH, an autosomal recessive pattern has been noted
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(ARH) was found to be caused by mutations in the LDL
Receptor Adaptor Protein 1 (LDLRAP1) also referred to
as the ARH g e n e[ 7 ] .T h eg e n ei sm a p p e dt o1 p 3 6 - 3 5
[31] spanning ~25 Kb with 9 exons coding for a 308 aa
protein. In ARH, the internalization of the ligand-recep-
tor complex cannot occur and all the LDL receptors
accumulate on the cell membrane. ARH is extremely
rare compared to ADH, and the number of patients
described to have defects in the ARH gene does not
exceed 100 [32]. ARH was initially described in Sardi-
nian and Lebanese families, but later found in American,
Iranian, Japanese, Mexican, Asian, Indian, English, Turk-
ish, and Syrian families [32-34].
Genotype Phenotype Correlations
LDLR mutations show a gene dosage effect, and a classical
presentation of homozygous versus heterozygous FH
patients has been documented. However, with the
advances in sequencing strategies it became clear that
LDLR mutations did not describe it all. Many patients with
severe or moderate phenotypes did not carry any LDLR
mutation. Later studies showed Familial Defective ApoB
[5], ARH [7], and more recently PCSK9 [6] as possible
explanations for an LDLR defect-negative FH phenotype.
LDLR
Table 2 shows phenotype comparisons between the four
different genes involved in FH. In general, the classical
ADH patients with LDLR mutations have the worst
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Figure 1 Molecular Pathways of Disease in Familial Hypercholesterolemia (1) The LDL receptor on the surface of hepatocytes binds ApoB-
100 of the LDL particle forming a complex. (2) A clathrin-coated pit is formed and the ligand-receptor complex is endocytosed via interactions
involving the LDLR Adaptor Protein 1 (LDLRAP1). (3) Inside the hepatocyte, the complex dissociates, the LDLR recycles to the cell membrane, (4)
and free cholesterol is used inside the cell. (5) PCSK9 serves as a post-transcriptional inhibitor of LDLR. It is secreted and inhibits LDLR through
cell-surface interactions. (6) The presence of an intracellular pathway for PCSK9-mediated LDLR inhibition is still a subject of controversy. (7) In
response to decreased cholesterol such as during treatment with statins, Steroid Response Element Binding Protein (SREBP) binds to the Steroid
Response Element (SRE) on the DNA and induces the transcription of the LDLR. (8) The sterol-responsive nuclear receptor LXR on the other hand
responds to increased intracellular cholesterol inducing the transcription of IDOL, a recently discovered molecule that induces the ubiquitin-
mediated degradation of the LDLR. Clouds in the figure refer to genes in which mutations have been associated with increased LDL-C levels.
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response to lipid-lowering therapy. Homozygotes usually
necessitate LDL apheresis therapy otherwise they die of
cardiovascular events as young as adolescence. Hetero-
zygotes have moderately elevated lipid levels, external
manifestations by adulthood or not at all, and premature
cardiovascular disease [1,8,9].
ApoB-100
ApoB-100 mutations show incomplete penetrance, so
patients with Familial Ligand-Defective Apolipoprotein
Table 2 Gene defects involved in FH and their effect on the phenotype
Gene Exon Number of Sequence Variants Function/Protein Domain Effect on the Phenotype
LDLR 1 79 Signal sequence to the ER
2 82 LDL-binding domain
3 125
4 339 Gene dosage effect
57 1
6 91 Homozygous ® severe, resistant to therapy; death
7 105 EGF-precursor like domain
8 106
9 145 Heterozygous ® variable; depends on mutation.
10 110
11 77
12 96 among all other genetic causes of FH
13 72
14 100
15 41 OLS environmental, and other metabolic factors.
16 38 Transmembrane
Cytoplasmic
18 4
ApoB 26 3* Binding region to the LDLR Less severe phenotype than LDLR mutations
PCSK9 13 2
2 17 Enhanced binding to LDLR Gain of function mutations cause
35
4 14 hypocholesterolemia
52 2
Polymorphisms in PCSK9 can affect the phenotype
64
77
81 2
91 8
10 9
11 5
12 16
LDLRAP1/ARH 11 4
2 1 Can be similar to classical homozygous FH, but has
31
4 6 (PTB) domain, which is the
5 2 responsible for cholesterol
68
More responsive to lipid-lowering therapy
76
81
*Many sequence variants exist in the ApoB gene. Only sequence variants involved in FH are mentioned here.
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patients with LDLR mutations [24]. Still in many
instances however, heterozygous ApoB defective patients
can be clinically indistinguishable from heterozygous
LDLR mutation patients. It was estimated that at least
2-5% of FH patients in lipid clinics are due to ApoB-100
mutations [24]. Considering ApoB-100 mutations is par-
ticularly important in populations where it is known to
be common, namely European and North American
[24], and less important in populations where it is rarely
reported such as Arabs and Middle Easterns [35].
ARH
ARH also shows some phenotypic differences from the
classical LDLR mutants. Patients have lower lipid levels,
traditionally observed to be somewhere between the levels
seen in heterozygous and homozygous ADH patients.
However, this does not always hold true, and there seems
to be a great variability of the phenotype between patients
in ARH, even within the same family [36]. A report of
LDL kinetic studies on one patient with Turkish decent
harboring an ARH mutation showed that the LDL cata-
bolic rate was delayed up to three-fold, making the patient
indistinguishable from patients with homozygous LDLR
mutations [37]. In general, ARH patients show a better
response to lipid-lowering therapy than the ADH patients,
and they rarely require LDL apheresis [38]. Some studies
also reported increased HDL levels in ARH compared to
ADH. The incidence of cardiovascular events in ARH also
tends to be delayed and they rarely have any in adoles-
cence [36]. Most importantly in FH is the family history.
LDLRAP1 mutations should always be suspected in
patients who are products of consanguineous marriages,
in typical populations, and with an autosomal recessive
pattern of inheritance.
PCSK9
The discovery of PCSK9 has added a lot to the phenoty-
pic understanding of FH. We have established earlier that
gain of function mutations in this gene cause hypercho-
lesterolemia and loss of function mutations cause hypo-
cholesterolemia, and that the gene is greatly polymorphic
with population differences. This has established PCSK9
as a modifier gene in FH, which causes the significant
phenotypic variability even in patients carrying the same
LDLR mutation [39]. Many studies have looked at the
presence of PCSK9 sequence variants on top of LDLR
mutations [39-41]. For some combined mutants, the phe-
notype is as severe as that of homozygous LDLR mutants
[27].
The Diagnostic Gap in FH
Still many clinically diagnosed FH patients fail to show
any mutation in these four genes. This diagnostic gap is
observed in most clinically diagnosed FH cohorts who
are screened for mutations. Canadians have studied this
diagnostic gap in Ontario and showed that exon-by-exon
sequencing analysis (EBESA) diagnosed only two thirds
the FH patients [42]. Using the Multiplex Ligation-
Dependent Probe Amplification (MLPA) technique to
detect copy number variations (CNVs) [43], they could
detect an abnormality in two thirds of the remaining gap,
reducing it from 30% to 10% [42]. Their findings sug-
gested that heterozygous LDLR CNV’s are associated
with more severe phenotypes and they are usually missed
in EBESA [22]. Another major explanation of the diag-
nostic gap is the presence of mutations in other unknown
novel genes that are involved in cholesterol metabolism.
More mapping studies to look for novel genes involved
in FH are needed to fill the diagnostic gap.
Variability of the Phenotype
FH is a disease that shows great phenotypic variability
[44]. The polygenetic nature of the disease is being
enhanced with the discovery of more modifier genes,
which explains a large part of this phenotypic variability.
In our cohort of Lebanese FH patients, we identified many
heterozygotes for the Lebanese allele mutation in the
LDLR, yet having normal lipid levels on no therapy [10].
S of a rw eh a v eb e e nr e f e r r i n gt ot h ep h e n o t y p eo fF H
patients in terms of lipid levels only. However, other phe-
notypic measures in this population include onset of
hypercholesterolemia, onset and degree of atherosclerosis,
cardiovascular measurements such as aortic stenosis, caro-
tid plaques, and intima-media thickness, cardiovascular
morbidity and mortality, and response to lipid-lowering
therapy among others. All these phenotypic measures are
the result of not only lipid levels, but also a combination
of genetic, metabolic, and environmental factors. People
carrying the same mutation can have different lipid levels,
and certain populations have moderate phenotypic expres-
sion of apparently severe mutations [21,45]. The type of
LDLR mutation has been shown to correlate with the
response to statin therapy [46]. Polymorphisms in lipid
modifier genes, such as apolipoproteins, particularly ApoE,
can significantly affect the FH phenotype [47]. Conven-
tional risk factors for atherosclerosis such as smoking,
diet, hypertension, and diabetes are also additive in FH
[48,49]. The levels of lipoprotein (a) have been correlated
with atherosclerosis and could also explain a variable phe-
notype or a paradoxical case of FH [50].
The Clinical Diagnosis of Familial Hypercholesterolemia
The Three Sets of Clinical Criteria for the Diagnosis of FH
Early diagnosis of heterozygous FH allows for prompt
treatment and prevention of morbidity and mortality from
premature cardiovascular disease. Tremendous efforts
have been made to improve the early diagnosis of this
population, yet, there is no single internationally accepted
set of criteria for the clinical diagnosis of FH. There are
three sets of statistically and genetically validated criteria
however that are most commonly used: the Dutch [51],
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MEDPED developed two sets of criteria distinguishing
between the general population and close relatives of
known FH patients. Criteria differ in each group due to
the statistical component of a pre-determined probability.
The statistical criteria developed are based solely on lipid
levels and age, and they are highly sensitive and specific
[53]. (Table 3) The Simon Broome Register Group in the
UK as well as the MEDPED group in the Netherlands
developed their criteria by classifying definite, probable,
and possible diagnoses of FH. Unlike the US criteria,
which used only lipid levels, the UK and Dutch criteria
use family history, personal history, and physical signs in
addition to the cholesterol levels [51,52].
Advantages and Disadvantages of Clinical Diagnosis
Although the above clinical criteria for diagnosis might
be helpful in diagnosing relatives of known FH patients,
they are not accurate in diagnosing index cases in the
general population. They are very helpful though in
avoiding the informal assessment of patients, which is
very often a weak predictor of FH. The advantage of
clinical criteria is also their low cost as they depend
solely on history taking, physical exam, blood lipid pro-
file testing, and possibly noninvasive cardiovascular test-
ing. Clinical diagnosis will fail to distinguish between
the classical FH due to LDLR mutations and the other
genetic causes of FH such as ApoB-100, ARH,a n d
PCSK9, or even non-familial hypercholesterolemia such
as secondary hypercholesterolemia, sitosterolemia, and
others. More importantly, clinical diagnosis could miss a
considerable proportion of the FH patients, particularly
those with a mild phenotype and the pediatric popula-
tion in whom the phenotype has not appeared yet. Very
often, a myocardial infarction is the first presenting sign
in many FH patients. Finally, clinical diagnosis will not
allow for understanding known genotype phenotype cor-
relations such as the better response to statin therapy in
ApoB-100 and ARH compared to LDLR mutations.
Table 3 Criteria for the Clinical Diagnosis of Familial Hypercholesterolemia
MEDPED Criteria ( USA)
Total Cholesterol (LDL-C) levels in mg/dL Comments
Age 1
st degree
relative
2
nd degree
relative
3
rd degree
relative
General
Population
<18 220 (155) 230 (165) 240 (170) 270 (200)
20 240 (170) 250 (180) 260 (185) 290 (220) 98% specificity
30 270 (190) 280 (200) 290 (210) 340 (240) 87% sensitivity
40 + 290 (205) 300 (215) 310 (225) 360 (260)
Simon Broome Criteria (UK)
Total Cholesterol
(LDL-C) in mg/dL
290 (190) in
adults, or
260 (155) in
pediatrics
AND DNA mutation Definite FH
Tendon xanthomas in the patient or in a 1
st or 2
nd degree relative Probable FH
Family history of MI at age <50 in 2
nd degree relative or at age <60 in 1
st degree
relative
OR
Family history of total cholesterol >290 mg/dL in 1
st or 2
nd degree relative
Possible FH
Dutch Criteria (The Netherlands)
1 point 1
st degree relative with premature cardiovascular disease or LDL-C >95
th
percentile, or
Personal history of premature peripheral or cerebrovascular disease, or
LDL-C between 155 and 189 mg/dL
Definite FH ( = or > 8 points)
2 points 1
st degree relative with tendinous xanthoma or corneal arcus, or
1
st degree relative child (<18 yrs) with LDL-C > 95
th percentile, or
Personal history of coronary artery disease
3 points LDL-C between 190 and 249 mg/dL Probable FH (6-7 points)
4 points Presence of corneal arcus in patient less than 45 yrs old
5 points LDL-C between 250 and 329 mg/dL Possible FH (3-5 points)
6 points Presence of a tendon xanthoma
8 points LDL-C above 330 mg/dL, or
Functional mutation in the LDLR gene
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Importance of a DNA Diagnosis
Genetic testing may give a definite diagnosis of FH if a
pathological mutation were detected [54]. Early and
definite diagnosis of FH has large benefits since it allows
for cholesterol lowering and risk prevention [54]. DNA
diagnosis is particularly important in equivocal cases
where lipid levels are mild with no clear external mani-
festations and with a family history of premature coron-
ary artery disease. These comprise the majority of the
cases of FH. In the extreme case, a patient with an
LDLR mutation might have LDL-C levels that fall within
the normal range. We have pinpointed few of these
cases in the Lebanese cohort. Although there is no evi-
dence that suggests that the mutation by itself poses an
independent risk for cardiovascular disease, identifying
such a mutation is clinically important since the patient
can develop high LDL-C levels at any point in life and
be missed. Finding a known pathogenic mutation might
prompt the clinician to screen more frequently for
hypercholesterolemia. This concept is most useful in
pediatrics where lipid levels might not be high enough
to make a diagnosis, although genetic testing in the
pediatric population remains a subject of controversy
[55]. A recent Cochrane review established the efficiency
and short-term safety of lipid-lowering therapy in chil-
dren with FH [56]. Hence, an accurate and early diagno-
sis might allow for treatment early on to prevent
cardiovascular disease morbidity and mortality.
Due to the paucity of data on genotype phenotype cor-
relations, clinical diagnosis will miss a large percentage of
FH patients. It is currently estimated that only 15 to 20%
of patients with FH are actually diagnosed [57,58]. A
study on 643 Danish probands could not even find a sin-
gle phenotypic characteristic to predict the existence of a
mutation [59]. A more recent study on 696 possible FH
patients in Portugal showed that genetic diagnosis for
cardiovascular risk stratification was superior to clinical
diagnosis using the Simon Broome criteria [60]. Not only
does finding a mutation allow for early diagnosis and
treatment, but it also has prognostic value. Different
mutations can dictate different directions of manage-
ment, such as the poorer response to lipid-lowering ther-
apy with certain LDLR mutations [46]. The identity of
the gene involved, dictates some aspects of the phenotype
as we already established in the genotype-phenotype cor-
relations. Although still not completely understood, such
correlations can potentially aid the clinician to decide on
how aggressive the treatment strategy will be. The effect
of the different LDLR mutations on the response to sta-
tins was studied in a limited number of small-scale stu-
dies in which several showed statistically significant
correlations [46]. Nevertheless, such pharmacogenetic
variability should be studied in large randomized control
trials, which is a little bit challenging in the presence of a
huge number of mutations in the LDLR.
Finally, the phenotypic expression of the FH mutation
may skip generations. This can occur for instance due to
the presence of modifier genes that can decrease LDL-C
levels or due to epigenetic factors that might also modu-
late the phenotype. In such cases, genetic testing may
have a prognostic significance for succeeding generations.
For this reason, discovery of a known pathogenic muta-
tion in an individual with normal LDL-C levels prompts
the clinician to screen other family members who might
have undiagnosed hypercholesterolemia.
Population Screening
In 1997, the WHO clearly established the benefits of a
DNA test for the diagnosis of FH and re-assured that it is
cost-effective [61]. However, with the evolving polygenetic
nature of the disease, several studies showed that genetic
diagnosis is hampered by the high cost, and genetic
screening for the population at large failed to show cost-
effectiveness due to the polygenetic nature of the disease
[62]. Nevertheless, for certain populations where one or
few known mutations cause the disease, and where the
prevalence of FH is higher than the general population,
population screening might be a good strategy. However,
until genetic epidemiology studies are conducted on these
populations, it will be hard to comment. Another limita-
tion of genetic population screening for FH is the variabil-
ity of the phenotype [44] and the paucity of data in
genotype phenotype correlations. Moreover, the pheno-
type is affected by many non-genetic factors as mentioned
earlier [47-49]. A recent meta-analysis showed a benefit
for population screening of children ages 1 to 9 years
using serum lipid levels and suggested that this strategy
might be helpful in identifying new cases in two genera-
tions, the children and their parents [63].
Cascade Screening
Cascade screening is another strategy that proved to be
cost-effective in genetic testing for FH. In cascade screen-
ing, an index patient is diagnosed initially clinically
through one of the clinical criteria listed in Table 3. A
DNA test confirms the mutation in the index patient.
Screening for the same mutation is undertaken in first
degree relatives to look for new cases. New confirmed
cases from the relatives are treated as new index cases
and their first degree relatives are screened. The first suc-
cessful model of national genetic cascade screening pro-
grams came from the Netherlands, which started in 1994
[64-66]. Norway also had successful results with their
program started in 2003 [67,68]. A large percentage of
the relatives screened ended up having definite FH, and
many of them were not on any therapy at the time of
diagnosis. Other countries that are starting to follow
similar strategies include Spain [69,70], Australia
and New Zealand [71,72], and Wales [73,74]. Table 4
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cascade screening programs as reported in the most
recent literature. It also lists mutation detection rates in
clinically diagnosed cohorts of patients from these coun-
tries [70,72,74,75] and others such as Denmark [76,77].
Mutation detection rates differ based on the original clin-
ical diagnosis of the cohort and on the mutation detec-
tion method. Various mutation detection methods are
used in different countries, including direct sequencing
[66], arrays [70], or Denaturing High Performance Liquid
Chromatography (DHPLC) and melting analysis [78,79].
Most screening strategies cover the LDLR and apoB-100
genes. An more novel screening strategy has been imple-
mented in Iceland whereby ancestors of FH probands
were traced and the oldest in each family lineage was
screened for the common LDLR Icelandic mutation, I4T
+2C [80]. This genealogical tracing might be superior to
the conventional first-degree relative approach in founder
populations.
Implementation Issues
Although cascade testing is a successful and cost-effec-
tive model for early diagnosis and treatment of FH, its
implementation carries many considerations. Currently
there is no study that could genetically identify the
Table 4 Mutation Detection Rates in Models of Genetic Screening for Familial Hypercholesterolemia
Country Start
Date
Years
assessed
Screening Relatives
of index
cases
Clinically
diagnosed
patients
Mutation
detection
rate
Mutation detection
method *
Clinical diagnosis
before screening
Reference
Netherlands 1994 16 Cascade 43891 - 36% Direct sequencing of
promoter and all exons of
LDLR and exons 26 and 29
of apoB; MLPA for large
deletions
N/A [66]
- - Patient
screening
- 1465 44% Stepwise screening
approach for LDLR and
apoB
The Dutch Criteria [75]
Norway 2003 5 Cascade 1805 - 44.8% Direct sequencing of
promoter and exons 1-17
and coding part of exon 18
of the LDLR and of codon
3500-containing PCR
fragment of the apoB gene;
MLPA for large deletions
N/A [67],[68]
Iceland 2003 N/A Systematic
family
screening
68 - 59% Screened for the common
LDLR Icelandic mutation
(I4T +2C) only
N/A [80]
Denmark - - Patient
screening
- 1053 40.4% Two out of three: [76]
1995 8 Patient
screening
- 408 33.1% (ii) Premature CAD
or family history of
CVD;
(iii) Presence of
xanthomas
[77]
Spain 2004 3 Patient
screening
- 825 55.6% Lipochip (Microarray that
includes 203 LDLR and 4
ApoB mutations)
Elevated familial
LDL-C with or
without familial or
personal histories
of premature CAD
or xanthomas
[69,70]
UK 2005 - Patient
screening
- 635 36.5% Definite or
probable FH
[74]
Cascade 296 - 56.1% N/A
New
Zealand
2004 4 Patient
screening
- 588 13% Elevated LDL-C,
lipid stigmata, or
family history of
premature CVD
[72,78,79]
Cascade 353 - 45% N/A
* For countries where mutation detection methods have changed over the years, the current mutation detection method at the time of the published study is
listed.
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and a large part of that is due to the polygenetic nature
of the disease. This complicates DNA testing and neces-
sitates the development of clear national guidelines that
provide step-by-step criteria for screening for particular
genes, based on previous genotype data on the popula-
tion. Such a national system would necessitate an infra-
structure to accommodate it, including education and
training, specialized clinics, outreach, etc. A genetic test-
ing program also carries with it ethical considerations,
psychological implications, and insurance coverage
issues [81].
The Lipids or the Genes?
Familial Hypercholesterolemia has been historically diag-
nosed and described based on lipid levels and family his-
tory. LDL-C levels also were the major determinant of
the phenotype. The advances in genetic testing have
added a different perspective to the disease. Not only
does genetic diagnosis provide a more accurate and early
diagnosis of FH, but it also provides information about
the phenotype and the prognosis that could not be
known from lipid levels alone. It also allows for the iden-
tification of more silent cases in the population, decreas-
ing the incidence of premature cardiovascular disease.
Although proven cost-effecti v e ,t h em o v ef r o ml i p i d st o
genes is challenging and will require huge efforts from
researchers and public health systems.
Conclusions
￿ Familial Hypercholesterolemia is caused by muta-
tions in LDLR, ApoB-100, PCSK9, and LDLRAP1.
￿ The terms homozygous and heterozygous refer to
a definite genotype of a patient with FH, while the
phenotype is a variable spectrum that could poten-
tially be described as mild, severe, or paradoxical.
￿ T h em a j o r i t yo fp e o p l ew i t hF Hh a v eam i l dp h e -
notype, are undiagnosed and untreated, and ulti-
mately develop premature cardiovascular disease.
￿ FH is a polygenetic disease with known and
unknown genes. It demonstrates a large variability in
the phenotype not only due to the polygenetic nat-
ure, but also due to non-genetic factors.
￿ AD N Ad i a g n o s i sf o rF Hi st h eo n l yd e f i n i t ed i a g -
nosis for the disease.
￿ Cascade genetic screening for FH is cost-effective
and should be adopted by national healthcare
programs.
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